Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful faithfully but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. My 1st CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire employment interview which I came away with a bad opinion of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, yet the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology as well as associated intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug program approval ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it has this individual treatment in addition to a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, several disease types, multiple delivering presentations and multiple publications.

Could all this be smoke and mirrors? That’s a question I have been asking myself through the really start of the interest of mine in this company. Judging with the multiples of thousands of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *